Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Comparing drug combinations for newly diagnosed acute myeloid leukemia

Tests chidamide, azacitidine and venetoclax in newly diagnosed acute myeloid leukemia.

Plain-language title generated from the registry record
Registry title: Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Key facts

Where
Dongguan, Foshan, Guangzhou, Haikou, Shenzhen, Zhanjiang, and Zhuhai, ChinaSee the 13 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed acute myeloid leukemia (AML) who have not yet had systemic anti-leukemia treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Newly diagnosed AML (WHO 2022 criteria), not acute promyelocytic leukemia (APL). ECOG 4 or lower.
Earlier treatment
No systemic anti-leukemia therapy before. Hydroxyurea, low-dose cytarabine and similar pretreatments to reduce tumor size are allowed.

Main reasons for not taking part

  • Known allergy to the study drugs
  • Resistance to azacytidine, azacitidine or Venetoclax
  • Cannot take oral medication
  • Uncontrolled active infection (bacterial, fungal or viral)
  • Uncontrolled major organ problems, such as heart failure or severe liver or kidney failure

Read by machine on 12 November 2026.

Where in China

  • Dongguan General HosptialDongguan, ChinaContact: yirong JiangTaking people
  • Foshan First People's HospitalFoshan, ChinaContact: Ying ZhaoTaking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Xin DuTaking people
  • Sun Yat-sen University Cancer CenterGuangzhou, ChinaContact: yang LiangTaking people
  • The Fifth Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: Runhui ZhengTaking people
  • The First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhou, ChinaContact: xueyi PanTaking people
  • The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: Zhenqian HuangTaking people
  • The First Affiliated Hospital of Jinan UniversityGuangzhou, ChinaContact: Liye ZhongTaking people
  • The second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: xu YeTaking people
  • Hainan General HosptialHaikou, ChinaContact: Li'e LinTaking people
  • Shenzhen Second People's HospitalShenzhen, ChinaContact: xin DuTaking people
  • Affiliated Hospital of Guangdong Medical UniversityZhanjiang, ChinaContact: Yuming ZHANGTaking people
  • Zhuhai General HosptialZhuhai, ChinaContact: xiaoliang LiTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Guangdong Provincial People's Hospital
Trial code
NCT06451861
Record updated
17 November 2025
Original description
To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemiaRead full original descriptionShow less

Randomized Study of ABC-14 Regimen ( AZA, Venetoclax and Chidamide) Compared With "3+7" Standard Induction Therapy or AB-14 (Venetoclax Combined With Azacitidine) for Newly Diagnosed Acute Myeloid Leukemia

To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia

Inclusion: Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments); Age ≥18 years old; ECOG≤4; The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.

Exclusion: Known history of allergy to the investigational drug; Inability to take oral medication; Combined with uncontrolled active infections (including bacterial, fungal or viral infections); Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc; Resistance to azacytidine, azacitidine, Venetoclax; Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.

ClinicalTrials.gov NCT06451861